BUZZ — Grail jumps as FDA raises no major concerns on cancer test
* Shares of cancer test maker Grail rise 34.6% to over seven-month high of $108.71 * U.S. FDA releases briefing documents showing no major safety or technical concerns regarding Grail's Galleri multi-cancer screening test * FDA focuses its panel discussion primarily on product labeling and whether data supports an expl